BioTechniques is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Journal
    • Aims and scope
    • Journal archive
    • Editorial board
    • For authors
    • Your editors: what do we do?

    Follow us on social media

  • Current issue
  • News
    • Latest news
    • Tech news
    • Events news
    • Company news

    Follow us on social media

  • Multimedia
    • Downloadable eBooks
    • Infographics
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • Features
    • Interviews
    • Opinion
    • In Focus
    • Spotlights
    • Companies
    • New products
    • Events

    Follow us on social media

  • Topics
    • Analytical chemistry
      • Biochemistry
      • Bioengineering and biophysics
      • Cancer research
      • Careers and Publishing
      • Cell and tissue biology
      • COVID-19
      • CRISPR
      • Computational biology
    • Diagnostics and preclinical
      • Drug discovery and development
      • Immunology
      • Lab design and machinery
      • Microbiology
      • Molecular biology
    • Nanomedicine
      • Neuroscience
      • PCR and sequencing
      • Plant and climate science
      • Proteomics
      • Veterinary science
      • Whole-genome studies

    Follow us on social media

  • Become a member
Don't miss our upcoming webinar on 'Metagenomics for pathogen surveillance' REGISTER NOW!

CRISPR

CRISPR gene editing technologies enable changes to be made to DNA at specific regions. These changes can involve DNA insertion or deletion, or base pair disruption and can lead to gene activation or inactivation.

Read more...
The first CRISPR – or clustered regularly interspaced short palindromic repeats – system to be used for gene editing was CRISPR/Cas9. There are now a number of different CRISPR systems used for gene editing purposes, with researchers continually developing new and improved systems for a multitude of different applications.

CRISPR/Cas9 is the most often used CRISPR gene editing system. When CRISPR/Cas9 is added to a cell along with a guide RNA (gRNA) molecule, the Cas9 enzyme binds to the gRNA, which is about 20 bases long and designed to be complementary to the target sequence within the DNA to be edited. The gRNA will also bind to the complementary region of DNA, and Cas9 will then cut the DNA at the desired target. The cell then recognizes that the DNA is damaged and tries to repair it.

During this repair process, alterations to the DNA sequence are introduced. In the case of Cas9, these mutations often disable a gene. Other enzymes can also be used that lead to different outcomes, including Cas12a. CRISPRi and CRISPRa use customized Cas proteins that do not cut or alter DNA but can turn genes on or off.

  • About BioTechniques
  • Advisory Board
  • Contact Us
  • Advertising
  • Permissions
  • Whitelist Emails
Contact
Contact Us
Office info

BioTechniques is powered by Taylor & Francis Group

BioTechniques, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom

Impact Factor 2.2 | CiteScore 2.0

  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 BioTechniques